RW-108 / RiverWalk Therapeutics - LARVOL DELTA

RW-108, a first-in-class adenosine A2 receptor inverse agonist for treating late-stage triple negative breast cancer (AACR 2025) - "Additionally, RW-108 enhances survival in metastatic models (53%) and anti-tumor T cells infiltration in the tumor microenvironment (70%). These compelling preclinical results support the continued development of RW-108 as a promising therapeutic for metastatic TNBC and other advanced cancers characterized by A2BR overexpression correlated with poor patient outcomes."

Late-breaking abstract • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer